Last reviewed · How we verify

Lamotrigine tablet — Competitive Intelligence Brief

Lamotrigine tablet (Lamotrigine tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Mood stabilizer. Area: Neurology / Psychiatry.

marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition Neurology / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Lamotrigine tablet (Lamotrigine tablet) — Dhaka Medical College. Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lamotrigine tablet TARGET Lamotrigine tablet Dhaka Medical College marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine generic "B" Lamotrigine generic "B" University of Cincinnati marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine Generic "A" Lamotrigine Generic "A" University of Cincinnati marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine (drug) Lamotrigine (drug) MaineHealth marketed Anticonvulsant / Antiepileptic drug Voltage-gated sodium channels; glutamate release inhibition
Brand lamotrigine Brand lamotrigine University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
Lamictal TM Lamictal TM Central Mental Clinic for Outpatients of Baku City marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition
lamotrigine (brand Lamictal) lamotrigine (brand Lamictal) University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Mood stabilizer class)

  1. University of Maryland, Baltimore · 4 drugs in this class
  2. Sanofi · 2 drugs in this class
  3. University of Cincinnati · 2 drugs in this class
  4. Mario Negri Institute for Pharmacological Research · 1 drug in this class
  5. Central Mental Clinic for Outpatients of Baku City · 1 drug in this class
  6. The University of Texas Health Science Center at San Antonio · 1 drug in this class
  7. University Hospitals Cleveland Medical Center · 1 drug in this class
  8. Dhaka Medical College · 1 drug in this class
  9. Korea Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lamotrigine tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/lamotrigine-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: